CONCORDANCE OF THE FDA-APPROVED COMPANION DIAGNOSTIC AND A NEXT-GENERATION SEQUENCING ASSAY KIT FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY IN OVARIAN CANCER

被引：0
|
作者：
Weichert, W. [1 ]
Qiu, P. [2 ]
Lunceford, J. [2 ]
Wehn, A. [2 ]
Yarunin, A. [3 ]
Marton, M. [2 ]
机构：
[1] Tech Univ Munich, Inst Pathol, Munich, Germany
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] AstraZeneca, Alderley Pk, England
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2021年 / 31卷
关键词：
D O I：
10.1136/ijgc-2021-ESGO.665
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
978
引用
收藏
页码：A375 / A375
页数：1
相关论文
共 41 条
  • [11] Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing
    Zhao, Qianying
    Yang, Jiaxin
    Li, Lei
    Cao, Dongyan
    Yu, Mei
    Shen, Keng
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (04)
  • [12] Landscape of homologous recombination repair (HRR) mutations in prostate cancer profiled by ctDNA next-generation sequencing
    Yen, Jennifer
    Gnerre, Sante
    Barbacioru, Catalin
    Helman, Elena
    Manor, Ohad
    Yablonovitch, Arielle
    Satya, Ravi Vijaya
    Liu, Leo
    Saam, Jennifer
    Fairclough, Stephen
    Nagy, Becky
    Lanman, Richard
    Talasaz, Darya Chudova AmirAli
    CANCER RESEARCH, 2020, 80 (16)
  • [13] Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test
    Cristescu, Razvan
    Liu, Xiao Qiao
    Arreaza, Gladys
    Chen, Cai
    Albright, Andrew
    Qiu, Ping
    Marton, Matthew J.
    BMC CANCER, 2022, 22 (01)
  • [14] YEvaluation of Homologous Repair Deficiency Status in Ovarian Carcinoma Using In-House Next-Generation Sequencing Panels
    Seth, A.
    Hussain, M.
    Jhala, N.
    Belogrivtseva, Y.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (11): : S93 - S94
  • [15] Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay
    Poh, Jonathan
    Kaur, Harvinder
    Ho, Jia Min
    Choudhury, Yukti
    Tan, Min-Han
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [16] TP53-specific mutations serve as a potential biomarker for homologous recombination deficiency in breast cancer: a clinical next-generation sequencing study
    Huang, Yongsheng
    Ren, Shuwei
    Ding, Linxiaoxiao
    Jiang, Yuanling
    Luo, Jiahuan
    Huang, Jinghua
    Yin, Xinke
    Zhao, Jianli
    Fu, Sha
    Liao, Jianwei
    PRECISION CLINICAL MEDICINE, 2024, 7 (02)
  • [17] Improved detection of homologous recombination deficiency in Chinese patients with ovarian cancer: a novel non-exonic single-nucleotide polymorphism-based next-generation sequencing panel
    Wei, Bing
    Zheng, Jinxiang
    Jiang, Cai
    Zhang, He
    Zhang, Mingye
    Cheng, Taoran
    Li, Jun
    Wang, Zhizhong
    Deng, Lijun
    Wang, Li
    Xia, Qingxin
    Ma, Jie
    MOLECULAR ONCOLOGY, 2023, 17 (08) : 1666 - 1677
  • [18] Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer
    Sztupinszki, Zsofia
    Diossy, Miklos
    Krzystanek, Marcin
    Reiniger, Lilla
    Csabai, Istvan
    Favero, Francesco
    Birkbak, Nicolai J.
    Eklund, Aron C.
    Syed, Ali
    Szallasi, Zoltan
    NPJ BREAST CANCER, 2018, 4
  • [19] Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer
    Zsofia Sztupinszki
    Miklos Diossy
    Marcin Krzystanek
    Lilla Reiniger
    István Csabai
    Francesco Favero
    Nicolai J. Birkbak
    Aron C. Eklund
    Ali Syed
    Zoltan Szallasi
    npj Breast Cancer, 4
  • [20] Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing
    Wang, Hai-Yun
    Deng, Ling
    Li, Ying-Qing
    Zhang, Xiao
    Long, Ya-Kang
    Zhang, Xu
    Feng, Yan-Fen
    He, Yuan
    Tang, Tao
    Yang, Xin-Hua
    Wang, Fang
    CANCER RESEARCH AND TREATMENT, 2021, 53 (04): : 973 - 982
12345